Worsening of borderline symptoms under reboxetine treatment [3]

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 17, Issue 4, 2005, Pages 559-560

  Anghelescu, Ion ^a   Jänen, Britta ^a   Schindler, Frank ^a   Lammers, Claas Hinrich ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; MIRTAZAPINE; QUETIAPINE; REBOXETINE; SERTRALINE; VENLAFAXINE;

ADULT; BORDERLINE STATE; CASE REPORT; DISEASE COURSE; DISSOCIATIVE DISORDER; DRUG WITHDRAWAL; DYSTHYMIA; FEMALE; GALACTORRHEA; HUMAN; INSOMNIA; IRRITABILITY; LETTER; MAJOR DEPRESSION; MENTAL DISEASE; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SEDATION; SIDE EFFECT; SUICIDAL BEHAVIOR; WEIGHT GAIN;

EID: 29044442216     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.17.4.559     Document Type: Letter

References (3)

1. Burrows GD, Maguire KP, Norman TR: Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry 1998; 59(suppl 14):4-7
2. Southwick SM, Bremner JD, Rasmusson A, et al: Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol Psychiatry 1999; 46:1192-1204
3. Philipsen A, Richter H, Schmahl C, et al: Clonidine in acute aversive inner tension and self-injurious behavior in female patients with Borderline personality disorder. J Clin Psychiatry (in press)